PPMI Enters a New Era of Precision Medicine
Spring / Summer 2026 | Research 9
Since its inception 15 years ago, the Parkinson’ s Progression Markers Initiative( PPMI) has advanced our understanding of the disease by creating the world’ s largest Parkinson’ s biorepository and validating a biomarker tool that can detect the disease before symptoms appear. Now, PPMI is poised to transform the field yet again by using that data to help biologically define the disease, identify it earlier and build more targeted treatments— a strategy called precision medicine.
As such, the study is ready for a new name: the Parkinson’ s Precision Medicine Initiative.
Maggie Kuhl, who leads patient engagement at The Michael J. Fox Foundation and PPMI study recruitment, explains what this shift means for the future of Parkinson’ s treatment.
What does precision medicine mean for patients and families? MK: Precision medicine looks at the full picture— someone’ s genetics, biology, environment and lifestyle— and uses that information to guide care. For people with Parkinson’ s, that could mean earlier detection, more accurate diagnoses and treatments that are tailored to the individual.
Why change the study name now? MK: PPMI is a global research study designed to better understand Parkinson’ s. Tens of thousands of volunteers have stepped forward to share their experiences, health data and samples. Now, thanks to their contributions, PPMI is poised to move the field beyond a one-size-fits-all approach to Parkinson’ s treatment.
What encourages you the most about this new era of Parkinson’ s research? MK: For me, it’ s the sense of momentum and hope. We’ re connecting the dots in ways that create real optimism. The goal of precision medicine— getting the right treatment to the right person at the right time— feels more tangible than it ever has before.
Join the Parkinson’ s Precision Medicine Initiative today. Anyone age 18 + is eligible to volunteer: michaeljfox. org / ppmi